askbio.comCrawled Oct 16, 2026
AskBio’s gene therapy pipeline includes programs for Pompe disease, limb-girdle muscular dystrophy 2i, multiple system atrophy, Huntington’s disease, Parkinson’s disease, and congestive heart failure.
Brain Neurotherapy Bio, Inc. (BNB) announced its merger with Asklepios BioPharmaceutical, Inc. (AskBio), a Bayer company.
AskBio describes its gene therapy technology and offers opportunities for collaboration.
AskBio develops scalable AAV manufacturing capabilities using its Pro10 technology and GMP manufacturing facilities.
AskBio’s team has published hundreds of research papers on AAV gene therapy for genetic diseases.
AskBio announced the presentation of baseline participant characteristics from GenePHIT, a gene therapy trial for heart failure. The trial’s enrollment demonstrates the feasibility of conducting multinational gene therapy trials of this size.
AskBio announced that FDA approval of an AAV gene therapy for adults with hemophilia B marks a milestone for AAV therapeutics. The announcement highlights research contributions by co-founder R. Jude Samulski.
AskBio’s headquarters are in Research Triangle Park, North Carolina, with other U.S. locations in Philadelphia, Pennsylvania, and Arlington, Ohio.
Dee Commodore, Andy Holt, Candace Summerford, and Pamela Ghosh represented AskBio at the annual Harvard Career Fair presented by the GSAS Harvard Biotech Club.
AskBio’s board of directors is described as invested in the company’s success and the advancement of gene therapy technology.
AskBio began in 2001 with a mission to advance AAV technology and provide gene therapy.
AskBio supports a variety of programs and initiatives to educate healthcare professionals, raise genetic disease awareness, and provide support to nonprofit patient advocacy organizations.
AskBio partners with gene therapy patient advocacy groups to support and advance research for rare genetic diseases.
AskBio supports collaboration among genetic researchers and partners to improve gene therapeutics.
AskBio develops AAV gene therapies for genetic and complex disorders and has current clinical trials.
